6533b827fe1ef96bd1285add

RESEARCH PRODUCT

High frequency of BRAF V600E mutation in Iranian population ameloblastomas

Abbas KarimiA MemarhaPouyan AminishakibM-j Kharazi FardSamira DerakhshanA AbdollahiH MohammadpourH Saffar

subject

Proto-Oncogene Proteins B-rafendocrine system diseasesGene mutationIranlaw.inventionAmeloblastoma03 medical and health sciences0302 clinical medicinelawBiomarkers TumorMedicineNeoplasmHumansAmeloblastomaGeneral DentistryneoplasmsPolymerase chain reactionOral Medicine and Pathologybiologybusiness.industryResearch030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]digestive system diseasesOtorhinolaryngologyMonoclonalMutation (genetic algorithm)MutationUNESCO::CIENCIAS MÉDICASCancer researchbiology.proteinImmunohistochemistrySurgeryAntibodyNeoplasm Recurrence Localbusiness

description

Background Ameloblastoma is a common locally invasive but slow-growing neoplasm of the jaws with an odontogenic origin. Association between BRAF V600E mutation and clinicopathologic features and behavior of ameloblastoma remains controversial. This study aimed to evaluate BRAF V600E gene mutation and expression of its related proteins with clinicopathologic parameters in conventional ameloblastoma. Material and Methods 50 Formalin-fixed paraffin-embedded blocks were included in this study. Immunohistochemistry was done using rabbit monoclonal BRAF V600E mutation-specific antibody VE1. Quantitative real-time polymerase chain reaction assay was used for evaluating of BRAF V600E mutation. Results Expression of BRAF V600E antibody was Positive in 42 out of 50 cases (84%). 46 (92%) out of 50 specimens showed BRAF V600E mutation. There were 13 cases of recurrence (26%). 3 out of 4 cases with negative mutations did not show recurrence. Conclusions We report the highest frequency (92%) of BRAF V600E mutation in ameloblastomas in the Iranian population. Although there was not a significant association between BRAF V600E‑positive immunoexpression and recurrence and clinicopathologic parameters, its high frequency could emphasize its role as a therapeutic marker in the future. Key words:Conventional ameloblastoma, BRAF V600E, recurrence.

10.4317/medoral.23519https://hdl.handle.net/10550/77151